In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and For an adult with type 2 diabetes mellitus who requires substantial weight loss, what are the recommended use, dosing, regulatory approval status, and contraindications of tirzepatide compared with cagrilintide, and what alternative Current Strategies in Managing Obesity STRIVE Obesity Efficacy and Safety of Tirzepatide for Weight Management in Non Diabetic Obese Individuals: A Narrative Review